Get started
Author

Anzhelika Vorobyeva

Observed names: A. G. Vorobyeva, A. Vorobyeva, A.G. Vorobyeva, Anzhelika G. Vorobyeva, Vorobyeva, Anzhelika
ORCID: 0000-0002-4778-3909
Observed ORCID: 0000-0002-4778-3909
OpenAlex ID: A5002404985
Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer
2020 · Olga Bragina, Emma von Witting, et al. · Journal of Nuclear Medicine · 64
Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
2021 · Olga Bragina, Vladimir Chernov, et al. · Journal of Nuclear Medicine · 59
PDF
Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu‐DOTAGA‐PEG 2 ‐RM26
2019 · Bogdan Mitran, Sara S. Rinne, et al. · International Journal of Cancer · 49
PDF
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties
2019 · Sergey Deyev, Anzhelika Vorobyeva, et al. · Molecular Pharmaceutics · 48
Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3
2019 · Anzhelika Vorobyeva, Alexey Schulga, et al. · Scientific Reports · 46
PDF
Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging
2015 · Anzhelika G. Vorobyeva, Michael Stanton, et al. · PLoS ONE · 44
PDF
Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
2018 · Anzhelika Vorobyeva, Olga Bragina, et al. · Contrast Media & Molecular Imaging · 41
PDF
Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
2017 · Dominik Summer, Javad Garousi, et al. · Molecular Pharmaceutics · 36
PDF
Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
2018 · Mohamed Altai, Charles Dahlsson Leitao, et al. · Cells · 33
PDF
Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
2020 · Tianqi Xu, Haozhong Ding, et al. · Cancers · 32
PDF
Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1
2019 · Sergey M. Deyev, Anzhelika Vorobyeva, et al. · International Journal of Biological Macromolecules · 31
PDF
Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours
2018 · Javad Garousi, Sarah Lindbo, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 31
PDF
Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
2020 · Anzhelika Vorobyeva, Elena Konovalova, et al. · International Journal of Molecular Sciences · 29
PDF
Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6
2019 · Emma von Witting, Javad Garousi, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 29
PDF
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers
2019 · Charles Dahlsson Leitao, Sara S. Rinne, et al. · International Journal of Molecular Sciences · 29
PDF
Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
2019 · Anzhelika Vorobyeva, Alexey Sсhulga, et al. · International Journal of Oncology · 29
PDF
Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
2021 · Maryam Oroujeni, Sara S. Rinne, et al. · International Journal of Molecular Sciences · 28
PDF
On the prevention of kidney uptake of radiolabeled DARPins
2020 · Mohamed Altai, Javad Garousi, et al. · EJNMMI Research · 28
PDF
Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion
2024 · Sergey M. Deyev, Maryam Oroujeni, et al. · International Journal of Molecular Sciences · 26
PDF
Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
2019 · Anzhelika Vorobyeva, Alexey Schulga, et al. · International Journal of Molecular Sciences · 26
PDF
Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting
2019 · Kristina Westerlund, Anzhelika Vorobyeva, et al. · Biomaterials · 26
PDF
Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
2019 · Haozhong Ding, Mohamed Altai, et al. · Cancers · 25
PDF
Influence of composition of cysteine-containing peptide-based chelators on biodistribution of 99mTc-labeled anti-EGFR affibody molecules
2018 · Maryam Oroujeni, Ken G. Andersson, et al. · Amino Acids · 25
PDF
Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
2023 · Yongsheng Liu, Tianqi Xu, et al. · Cancers · 24
PDF
Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts
2021 · Maryam Oroujeni, Hanna Tano, et al. · Journal of Nuclear Medicine · 23
PDF
Works count: 97
Citation count: 1,483
H-index: 24
I10-index: 57
Year
Topic
Type